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Gaucher disease is the most common of the lysosomal storage disorders (Beutler & Grabowski, 1995) . Glucocerebrosidase deficiency results in accumulation of its substrate, glucocerebroside, in macrophages. Accumulation of the storage material in these cells gives the characteristic appearance of the Gaucher cells in liver, spleen and bone marrow. Type 1 Gaucher disease is the most prevalent form and is distinguished from types 2 and 3 by the absence of neurological symptoms. The clinical picture is very heterogenous and is characterized by varying degrees of hepatosplenomegaly and bone lesions (Beutler & Grabowski, 1995) . Pancytopenia occurs frequently and is the result of consumption of blood cells by the sometimes massively enlarged spleen and of marrow infiltration with Gaucher cells. In general, bleeding disorders in Gaucher disease patients are believed to be caused by thrombocytopenia. In addition to a low platelet count, significant clotting factor deficiencies have been described, which may also contribute to the bleeding tendency (Berrebi et al, 1992; Billet et al, 1996; Boklan & Sawitsky, 1976; Humphries & Hess, 1994; Sawitsky & Boklan, 1972; Seligsohn et al, 1976; Yates et al, 1992) . In these reports, only a few parameters of coagulation have been studied and information about splenic status is usually lacking. It has been suggested that an enlarged spleen, irrespective of the underlying disorder, is associated with a reduction in the concentration of clotting factors, which is supported by the observation that splenectomy corrected the deficiencies in a patient with Gaucher disease (Gerrits et al, 1974; Vreeken et al, 1967) .
Treatment of Gaucher disease with enzyme supplementation therapy (alglucerase) has become available in the last decade. Reversal of hepatosplenomegaly and cytopenia has well been documented, using different doses of enzyme (Barton et al, 1991 (Barton et al, , 1990 Figueroa et al, 1992; Hollak et al, 1995; Zimran et al, 1994 Zimran et al, , 1993 . It is of interest to know whether the coagulation abnormalities improve upon treatment with enzyme supplementation therapy. In a recent study no effects of enzyme supplementation therapy were reported, but specific data were not given (Billet et al, 1996) .
The aim of the present study was to document the parameters of coagulation and fibrinolysis in a relatively large group of both non-splenectomized and splenectomized type 1 Gaucher disease patients and to evaluate the effect of enzyme supplementation therapy in relation to the the wellknown response parameters, i.e. changes in hepatic and splenic volumes and platelet count.
PATIENTS AND METHODS

Patients.
A total of 30 patients (age 15-66 years) who started enzyme supplementation therapy at the Academic Medical Centre between January 1992 and April 1995 were included in this study. The characteristics of the patients are shown in Table I . A diagnosis of type 1 Gaucher disease was confirmed by the demonstration of decreased glucocerebrosidase activity in leucocytes or urine (Aerts et al, 1986; Daniels & Glew, 1982) and genotyping . The severity of the disease was mild to severe according to the severity scoring index (SSI; Zimran et al, 1992) . 14/30 patients had been splenectomized prior to the start of treatment.
Enzyme supplementation therapy. Patients started with a low dose of alglucerase (Ceredase ® , Genzyme, Mass., U.S.A.) of 1 . 15 U/kg, three times a week (15 U/kg per month), except for patients 28 and 30 who received 30 U/kg every 2 weeks. Measurements of liver and spleen volume were obtained in all patients before treatment and after 6 and 12 months of treatment by means of spiral computerized tomography (CT). The accuracy for liver and spleen volume measurements by conventional CT is reported to be 3-5% (Breimann et al, 1982; Heymsfield et al, 1979) . By using spiral CT, measurement of 26 cm of the length of an organ within a single breath-hold is possible, eliminating misregistration of adjacent scan slices (Bluemke & Fishman, 1992) . Reductions in organ volumes were calculated as percentage reduction from the volume measured 6 months earlier and corrected for a change in bodyweight (Barton et al, 1993) . Coagulation studies. Measurements were performed before and after 6 and 12 months of alglucerase treatment. At 12 months, data were available in 26/30 patients. Plasma was prepared by mixing nine volumes of venous blood with one volume of 3 . 8% sodium citrate and centrifuging for 20 min at 1800 g. Activated partial thromboplastin time (aPTT) and prothrombin time (PT) were measured according to standard methods. Coagulation factor activity was measured using automated one-stage clotting assays. Antigenic levels of factor VIII, IX and XII were measured with immunological assays, as described previously (Cejka, 1982; Nuijens et al, 1988) . Plasma levels of antithrombin III, protein C and protein S were determined by amidolytic assays (Chromogenix, Mölndal, Sweden) (Peters et al, 1982; Sturk et al, 1987) . Plasminogen and a2-antiplasmin were measured by automated amidolytic techniques as described previously (Peters et al, 1982) . Thrombin-antithrombin complexes were measured by ELISA (Behringwerke AG, Germany) (Hoek et al, 1988) . D-dimer levels were determined using a commercially available ELISA kit (Asserachrom, Stago, Asnieres, France). Plasmin-a2-antiplasmin complexes were measured by RIA as described previously (Levi et al, 1995) .
Statistics. Comparisons between splenectomized and nonsplenectomized patients before treatment were performed by using the Mann-Whitney non-parametric test. Differences within the same groups before and after treatment were calculated by signed-rank test. Table II shows, in both splenectomized and non-splenectomized patients, the median and range of clotting times, coagulation factors and thrombin-antithrombin levels as well as the percentage of patients with values above or beneath the normal value. PT and aPTT were prolonged in 42% and 38% of patients respectively. The degree of clotting factor deficiencies was highly variable, with coagulation factor levels as low as 15% in some patients. The most frequently encountered clotting factor abnormalities were deficiencies of factor V (fV), factor X (fX) and factor II (fII). Fig 1 shows the levels of clotting factors II, V, VII and X for all patients. Factor V was decreased in almost all patients, although the reduction was not very serious (minimum level 30%). Lowest levels were observed for factor II, VII (fVII) and X. Severe deficiencies of factors II, VII and X were usually present in the same patient (correlation between fII and fX: r ¼ 0 . 76 between fX and fVII: r ¼ 0 . 54 between fII and fVII: r ¼ 0 . 58). To determine whether the observed deficiencies in coagulation factor activity were due to real reductions of protein concentration or due to aspecific assay problems caused, for instance, by high plasma concentrations of glucocerebroside, we measured antigenic levels of selected coagulation factors (fVIII, fX and fXII) in plasma of patients with deficiencies in either of these factors. In all instances the reductions in clotting factor activity coincided with low antigenic levels of the particular protein (data not shown).
RESULTS
Coagulation and fibrinolysis in Gaucher patients
To assess the overall presence of coagulation activation, plasma levels of thrombin-antithrombin (TAT) complexes were determined (Table II) . They were found to be elevated in 46% of the patients, suggesting that the deficiencies in clotting factors were due to consumption caused by enhanced ongoing low-grade activation of coagulation rather than due to impaired synthesis with a subsequent hypo-coagulative state.
As shown in Table III , coagulation inhibitors were also found to be deficient. Particularly, deficiencies of protein C were present in 30% of the patients with a minimum level of 34%. Plasma levels of protein S and antithrombin III were Significant differences between non-splenectomized and splenectomized patients are marked: * P < 0 . 05, † P < 0 . 005. reduced in a small number of patients (11% and 3% respectively).
Results of fibrinolytic studies are presented in Table IV . Reduced levels of plasminogen and a2-antiplasmin occurred in 37% and 20% of patients respectively. Again, overall fibrinolytic activity, as reflected by plasma levels of plasmina2-antiplasmin complexes and D-dimer, was enhanced in a significant number of patients, indicating that the depletion of fibrinolytic proteins is the result of continuing activation of the fibrinolytic system.
Influence of the spleen on coagulation and fibrinolytic parameters
Significant differences in clotting factors were found between non-splenectomized and splenectomized patients. PT was significantly more prolonged in non-splenectomized as compared to splenectomized patients (median 15 . 4 s versus 14 . 6 s respectively; P < 0 . 05). Most coagulation factor levels tended to be lower in non-splenectomized patients (Table II) ; significant differences were found for clotting factor VIIIc and fibrinogen. Remarkably, thrombin-antithrombin complexes were higher in splenectomized patients as compared to non-splenectomized patients (median 6 . 5 mg/l and 3 . 3 mg/l respectively; P < 0 . 05). In non-splenectomized patients, TATcomplexes were not associated with spleen volume (r ¼ 0 . 343).
A significant inverse correlation was found between factor V and spleen volume (r ¼ ¹0 . 776) (Fig 2) . Platelet count was also inversely associated with splenomegaly (r ¼ ¹0 . 671). Factor V correlated with platelet count (r ¼ 0 . 676). None of the other coagulation parameters correlated significantly with spleen and/or liver volume or platelet count, although a trend was found for lower factors II, X and XI in association with lower platelet count and larger spleens (P ¼ 0 . 2, 0 . 06 and 0 . 07 for correlation with platelet count respectively; P ¼ 0 . 08, 0 . 05 and 0 . 05 for correlation with splenic volume respectively).
Effects of enzyme supplementation therapy
Spleen and liver volumes decreased by 22 . 5% and 12% Plas.g. ¼ plasminogen; a2ap ¼ a2-antiplasmin; PAP ¼ plasmina2-antiplasmin complex. Significant differences between non-Sx and Sx patients: * P < 0 . 05, † P < 0 . 005.
Fig 2.
Correlation between pre-treatment spleen volume and factor V levels.
respectively after 6 months of treatment and by a further 10% and 8% between 6 and 12 months. Four patients were excluded from the analysis of liver volume because either they had a normal volume before treatment (patients 3, 10 and 25) or no measurement had been performed (patient 16). In one patient spleen volume was not completely measured at 6 months and was therefore excluded from analysis of spleen volume (patient 18).
After 6 and 12 months of treatment, aPTT significantly decreased in all patients (P < 0 . 05 at 6 months and P < 0 . 005 at 12 months), whereas PT remained unchanged. This change in aPTT was most clearly present in the nonsplenectomized group. Both factor V and platelet count increased in the non-splenectomized group after 12 months (P < 0 . 05 and P < 0 . 01 respectively). No significant association between the decrease in splenic volume and the increase in either platelet count or factor V could be established. Except for factor V, no significant increase in the clotting factors occurred. Protein C increased significantly in the non-splenectomized group after 12 months of treatment (P < 0 . 01), whereas levels of protein S and AT III remained unchanged. Thrombin-antithrombin complexes and Ddimer levels decreased at 6 months in both groups (P < 0 . 05 and P < 0 . 005 respectively), although the difference at 12 months was not significant from baseline. A decrease in fibrinolytic activity after treatment with enzyme supplementation therapy was also indicated by significantly lower levels of PAP complexes (Fig 3) .
DISCUSSION
Although decreased clotting factor levels have been documented in a small number of published case-histories, our study is the first report on a relatively large group of type 1 Gaucher disease patients who were systematically studied for coagulation abnormalities. In summary, very low levels of almost all coagulation factors were found, although the severity of the deficiencies was variable in the patients. Usually, severe deficiencies of several factors, especially factors II, VII and X were established concomitantly in individual patients, suggesting that the deficiencies are the result of the same process. In addition to low levels of coagulation factors, coagulation inhibitor levels were also moderately reduced, particularly protein C. Overall coagulation activity, as reflected by a marker for thrombin generation (i.e. thrombin-antithrombin complexes), was increased. Simultaneously, markers for activation of the fibrinolytic system, such as levels of D-dimer and plasminogen-a2-antiplasmin complexes were enhanced. These data are compatible with the hypothesis of ongoing low-grade activation of coagulation in type 1 Gaucher disease patients, resulting in consumption of various clotting factors, and balanced by simultaneous activation of the fibrinolytic system. The absence of deficiencies in factor VIIIc agrees with this hypothesis, since levels of this clotting factor are usually normal or even elevated in cases of severe intravascular coagulation (Marder et al, 1994) .
Since Gaucher disease affects the liver, it is possible that coagulation factor deficiencies are due to inadequate production by the liver. Gaucher cell infiltration in the liver leads to mild liver enzyme abnormalities, but hepatocyte function is usually preserved ( James et al, 1981) . In our study, non-splenectomized patients had no elevations of liver enzymes and in splenectomized patients slightly elevated transaminases, alkaline posphatase and gglutamyltransferase activities were found. Antithrombin III levels, which are usually decreased when liver function is impaired, were normal in all but one patient (Table III) . This indicates that the observed deficiencies in coagulation factors could not simply be ascribed to disturbed hepatocyte function.
Boklan & Sawitsky (1976) described a deficiency in factor IX in 11 patients with Gaucher disease and persistence of this abnormality after splenectomy in one patient. The finding of a decrease in the half-life of exogenously administered factor IX concentrate in this patient (Boklan & Sawitsky, 1976 ) is compatible with the hypothesis of continuing low-grade intravascular coagulation. A recent study in nine Gaucher disease patients, however, did not confirm the presence of factor IX deficiency, but low levels of factors XI, II, V and VIII were found in some patients (Billet et al, 1996) . Isolated factor XI deficiencies have been reported earlier in some cases of Gaucher disease (Berrebi et al, 1992; Freedman & Puliafito, 1988) . It has been established that factor XI deficiency occurs frequently in the Askenazi Jewish population, independent of the presence of Gaucher disease (Seligsohn et al, 1976) .
Our data suggest that the spleen may indeed contribute to the coagulation abnormalities: splenectomized patients had less severe clotting factor deficiencies compared to nonsplenectomized patients. The reverse correlation between the size of the spleen and factor V levels, and to a lesser extent with factors II, X and XI, supports this. It is hypothesized that the association between splenic size, factors II, V, X and XI and platelet count may be partially due to the clearance of both platelet count and clotting factors by the enlarged spleen. The correlation of factor V with platelet count could also be explained by the observation that factor V is also produced by platelets (Wencel-Drake et al, 1985) . Vreeken et al (1967) described a type 1 Gaucher disease patient with a deficiency in factor V and VIII before splenectomy, which normalized completely after removal of the spleen. The presence of fibrin deposits in the spleen after surgery supported their hypothesis that low-grade intravascular coagulation within the spleen was responsible for the deficiencies. The role of the spleen in the consumption of clotting factors is also suggested by Gerrits et al (1974) , who studied clotting abnormalities in six patients with splenomegaly, including the patient described by Vreeken. Decreased factor V and VII levels were found in addition to a low platelet count and low levels of plasminogen and fibrinogen in most patients, irrespective of the underlying disorder that caused the splenomegaly. Other clotting factors were not measured. Since levels of thrombin-antithrombin complexes are higher in splenectomized patients compared to non-splenectomized patients, it is possible that the spleen also plays a role in the enhanced clearance of these complexes. Reduction in splenic size upon treatment might thus influence the clearance of TAT levels, underestimating its decrease in non-splenectomized patients. Indeed, TAT levels decreased more in splenectomized patients as compared to non-splenectomized patients.
In the study by Billet et al (1996) it was mentioned in the discussion that no long-term effects of enzyme supplementation therapy on coagulation parameters were found, although 6/9 patients in the study were already on enzyme supplementation therapy and detailed data are lacking. In the present investigation, enzyme supplementation therapy appears to reduce the coagulation and fibrinolytic activity. The data suggest that this effect might well be due to the reduction in size of the spleen induced by this therapy, although no correlation between the reduction in splenic size and the change in coagulation parameters could be established. A more specific effect on the coagulation system can therefore not be excluded.
Although the spleen probably contributes to the observed coagulation abnormalities, the same abnormalities were also found in most of the splenectomized patients. In fact, the patient described by Vreeken et al (1967) was also included in our study and he developed factor V deficiency in the 25 years following splenectomy and prior to the institution of enzyme supplementation therapy. Additional factors are therefore responsible for the enhanced activation of coagulation and fibrinolysis in Gaucher disease patients. Recent insights point to a pivotal role of tissue factor in the initiation of coagulation activation. Tissue factor may be expressed on activated mononuclear cells. However, no studies have been carried out to establish the expression of tissue factor on Gaucher cells. In addition, several cytokines, including TNF, have proven to induce activation of coagulation and fibrinolysis (van der Poll et al, 1990 (van der Poll et al, , 1991 . In vitro observations have suggested a role for IL1 in the pathophysiology of Gaucher disease (Gery et al, 1981) . We did not find elevated TNF and IL6 levels in serum of type 1 Gaucher disease patients (unpublished data); however, increased local production can not be excluded. Further studies are needed to establish the possible role of cytokines in the pathophysiology of the coagulation disorder.
Although the coagulation abnormalities in Gaucher disease patients may seem severe, the clinical expression of this derangement is very modest. Bleeding problems appear to be related mainly to the severity of thrombocytopenia. In our study, mild bleeding diathesis (easily bruised, nose bleeds) was only found in the patients with low platelet counts and might also be associated with low levels of factor V and, to a lesser extent, factors II, X and XI, which appeared to be low in relation to low platelet counts. Disturbed platelet function has also been described in Gaucher disease patients. It has been suggested that plasma glucocerebroside may interfere with platelet function by adherence to the platelet membrane (Kelsey et al, 1994) . This phenomenon may also add to the bleeding tendency. The absence of severe bleeding problems suggests that the activation of both the coagulation and fibrinolytic system is sufficiently balanced to prevent severe bleeding. However, if bleeding occurs, or if the patient is subjected to an invasive procedure, the coagulation abnormalities observed in our study may well contribute to the bleeding tendency and supplementation of coagulation factors should be considered.
In conclusion, in type 1 Gaucher disease patients, severe coagulation abnormalities are found in a considerable number of patients. Our results suggest that low-grade ongoing activition of coagulation with subsequent depletion of coagulation factors and balanced by simultaneous activation of the fibrinolytic system may be responsible for these effects. Enzyme supplementation therapy restores some of the abnormalities.
